GURUFOCUS.COM » STOCK LIST » Industrials » Industrial Distribution » Sichuan Goldstone Asia Pharmaceutical Inc (SZSE:300434) » Definitions » Debt-to-Revenue

Sichuan Goldstone Asia Pharmaceutical (SZSE:300434) Debt-to-Revenue : 0.08 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Sichuan Goldstone Asia Pharmaceutical Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Sichuan Goldstone Asia Pharmaceutical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥116 Mil. Sichuan Goldstone Asia Pharmaceutical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ¥2 Mil. Sichuan Goldstone Asia Pharmaceutical's annualized Revenue for the quarter that ended in Mar. 2024 was ¥1,451 Mil. Sichuan Goldstone Asia Pharmaceutical's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 was 0.08.


Sichuan Goldstone Asia Pharmaceutical Debt-to-Revenue Historical Data

The historical data trend for Sichuan Goldstone Asia Pharmaceutical's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Goldstone Asia Pharmaceutical Debt-to-Revenue Chart

Sichuan Goldstone Asia Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 - 0.01 0.10

Sichuan Goldstone Asia Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.02 0.01 0.08 0.08

Competitive Comparison of Sichuan Goldstone Asia Pharmaceutical's Debt-to-Revenue

For the Industrial Distribution subindustry, Sichuan Goldstone Asia Pharmaceutical's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sichuan Goldstone Asia Pharmaceutical's Debt-to-Revenue Distribution in the Industrial Distribution Industry

For the Industrial Distribution industry and Industrials sector, Sichuan Goldstone Asia Pharmaceutical's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sichuan Goldstone Asia Pharmaceutical's Debt-to-Revenue falls into.



Sichuan Goldstone Asia Pharmaceutical Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Sichuan Goldstone Asia Pharmaceutical's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(112.116 + 2.712) / 1209.199
=0.09

Sichuan Goldstone Asia Pharmaceutical's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(115.922 + 2.287) / 1451.14
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Sichuan Goldstone Asia Pharmaceutical Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Sichuan Goldstone Asia Pharmaceutical's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Sichuan Goldstone Asia Pharmaceutical (SZSE:300434) Business Description

Traded in Other Exchanges
N/A
Address
8 Jiayuan Road, 8th Floor, District A1, Dadi Xinguanghua Plaza, Chengdu, CHN, 610072
Sichuan Goldstone Asia Pharmaceutical Inc is engaged in development and application of steel-reinforced plastic composite pipe technology, providing customers with steel-reinforced plastic composite pipes from pipe structure, production process to construction technology. The company is also engaged in research and development, production and sales of medicines and health products.

Sichuan Goldstone Asia Pharmaceutical (SZSE:300434) Headlines

No Headlines